THE PROGNOSTIC VALUE OF ONCOGENIC ANTIGEN-519 (OA-519) EXPRESSION AND PROLIFERATIVE ACTIVITY DETECTIVE BY ANTIBODY MIB-1 IN NODE-NEGATIVE BREAST-CANCER
THE PROGNOSTIC VALUE OF ONCOGENIC ANTIGEN-519 (OA-519) EXPRESSION AND PROLIFERATIVE ACTIVITY DETECTIVE BY ANTIBODY MIB-1 IN NODE-NEGATIVE BREAST-CANCER
复制标题
DOI：
10.1002/path.1711760405
复制
发表时间：
1995-08-01
影响因子：
7.3
通讯作者：
SOERENSEN, FB
中科院分区：
文献类型：
--
作者：
JENSEN, V;LADEKARL, M;SOERENSEN, FB
在118例低危乳腺癌患者的回顾性系列研究中，评估了致癌抗原519（OA - 519）表达和肿瘤增殖活性的预后价值。低危定义为腋窝淋巴结阴性、肿瘤直径小于或等于50mm，且无皮肤或深筋膜浸润的组织学证据（= T₁N₀M₀和T₂N₀M₀）。中位随访时间为104个月（范围5 - 143个月）。对福尔马林固定、石蜡包埋的组织进行OA - 519表达的免疫组化分析。使用一种Ki - 67等效单克隆抗体（MIB - 1）评估增殖活性，该抗体在微波预处理后可用于福尔马林固定、石蜡包埋的组织。约三分之一的肿瘤表达OA - 519，增殖细胞百分比（MIB - 1指数）在1% - 72%之间（中位数为17%）。通过多变量Cox分析，MIB - 1指数和OA - 519表达均具有独立的预后价值（2p≤0.01），因此联合免疫组化方法可能有助于筛选出可能从辅助治疗中获益的腋窝淋巴结阴性乳腺癌患者。
The prognostic value of oncogenic antigen 519 (OA-519) expression and tumour proliferative activity was evaluated in a retrospective series of 118 patients with low-risk breast cancer. Low risk was defined as negative axillary nodes, tumour diameter less than or equal to 50 mm, and no histological evidence of invasion of skin or deep fascia (= T(1)N(0)M(0) and T(2)N(0)M(0)). The median follow-up time was 104 months (range 5-143 months). Immunohistochemical analysis of OA-519 expression was performed on formalin-fixed, paraffin-embedded tissue. The proliferative activity was estimated using a Ki-67 equivalent monoclonal antibody (MIB-1), which is applicable on formalin-fixed, paraffin-embedded tissue after microwave pretreatment. OA-519 was expressed in about one-third of the tumours and the percentage of proliferating cells (the MIB-1 index) ranged between 1 and 72 per cent (median 17 per cent). Using multivariate Cox analysis, both the MIB-1 index and OA-519 expression were of independent prognostic value (2p less than or equal to 0 . 01), and the combined immunohistological approach may therefore be useful in selecting patients with node-negative breast cancer who might benefit from adjuvant therapy.